PMVP - Precision Oncology PMV Pharmaceuticals Reveals Early Data From Cancer Study In Pretreated Patients | Benzinga
PMV Pharmaceuticals Inc (NASDAQ: PMVP) announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE trial that showed PC14586 achieved efficacy in heavily pretreated patients across multiple tumor types and was well tolerated with a favorable safety profile.
Results are being presented in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Confirmed responses were observed in patients whose tumors were ...